AGO2 and non-small cell lung carcinoma: Taken together, above findings demonstrate that pS417‐AGO2 promotes NSCLC development and the high pS417‐AGO2 levels are positively correlated with NSCLC progression, indicating that high pS417‐AGO2 level is a risk factor of NSCLC, and it may be a potential therapeutic target.